2 registrations that name activated Charcoal as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
Phase
All 2 registrations
RecruitingNCT05471479
Activated CHARcoal in Poisoned Patient - Pilot Trial
Phase 4
Laval University
About 100 people
Started Jul 16, 2025
In plain words A Phase 4 study of activated Charcoal in people of any age, run by Laval University. It plans to enroll about 100 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people of any age. Conditions: Charcoal, Decontamination, Poisoning.
Adult and pediatric patients who presented to the hospital less than 6h after the ingestion of a potentially toxic dose of a carbo-adsorbable substance (substance adsorbed by activated charcoal ).
Patients who can receive the intervention within 6 hours of proven or suspected intoxication
The exclusion criteria are on the listing.
What it tests, as registered
Activated Charcoal; No activated charcoal
Registered summary
The goal of this clinical pilot trial is to determine the feasibility of the clinical trial. Then the large-scale CHARPP will be conducted in order to determine the efficacity of activated charcoal as a treatment for acute poisoning in a diverse population of both adults and children suspected of ingesting toxic substances that activated charcoal can adsorb. The full summary is on the listing.
Where, as registered
No US site; Canada (1).
RecruitingNCT06906874
Activated Charcoal Use in Chronic Kidney Disease Patients
Phase 2
Mansoura University
About 40 people
Starts Aug 2025 (estimated)
In plain words A Phase 2 study of activated Charcoal in people 18 and older, run by Mansoura University. It plans to enroll about 40 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: End Stage Renal Disease (ESRD); CKD 5D, Hemodialysis; CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder.
Adult aged ≥18 years with ESRD.
Patients who had been on stable maintenance hemodialysis (3 times weekly) for at least 6 months.
Patients receiving phosphate binders according to standard protocols established by kidney disease: Improving Global Outcomes (KDIGO).
The exclusion criteria are on the listing.
What it tests, as registered
Activated Charcoal; Phosphate Binders
Registered summary
Hyperphosphatemia management is initially based on restricting dietary phosphorus intake. Hyperphosphatemia is almost always seen in patients on dialysis and may contribute to progressive vascular calcification. Considering that activated charcoal is generally well-tolerated and may have a favorable side effect profile compared to conventional phosphate binders, it presents a promising alternative. Until now, no clinical trial has primarily investigated the effect of activated charcoal on hyperphosphatemia in dialysis patients.
Where, as registered
No US site; Egypt (1).
ClinicalTrials.gov lists 21 open registrations for this search, including ones where activated Charcoal is not a study arm or that are past the 2 we keep. Search them on ClinicalTrials.gov (opens in new tab).